Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Five-Year Overall Survival Analysis of the JIPANG Study: Pemetrexed or Vinorelbine Plus Cisplatin for Resected Stage II-IIIA Nonsquamous Non-Small-Cell Lung Cancer.
Kenmotsu H, Yamamoto N, Misumi T, Yoh K, Saito H, Sugawara S, Yamazaki K, Nakagawa K, Sugio K, Seto T, Toyooka S, Date H, Mitsudomi T, Okamoto I, Yokoi K, Saka H, Okamoto H, Takiguchi Y, Takahashi T, Tsuboi M. Kenmotsu H, et al. Among authors: okamoto i, okamoto h. J Clin Oncol. 2023 Dec 1;41(34):5242-5246. doi: 10.1200/JCO.23.00179. Epub 2023 Sep 1. J Clin Oncol. 2023. PMID: 37656928 Clinical Trial.
Phase II trial of amrubicin for treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301.
Onoda S, Masuda N, Seto T, Eguchi K, Takiguchi Y, Isobe H, Okamoto H, Ogura T, Yokoyama A, Seki N, Asaka-Amano Y, Harada M, Tagawa A, Kunikane H, Yokoba M, Uematsu K, Kuriyama T, Kuroiwa Y, Watanabe K; Thoracic Oncology Research Group Study 0301. Onoda S, et al. Among authors: okamoto h. J Clin Oncol. 2006 Dec 1;24(34):5448-53. doi: 10.1200/JCO.2006.08.4145. J Clin Oncol. 2006. PMID: 17135647 Clinical Trial.
A phase II study of cisplatin and irinotecan as induction chemotherapy followed by accelerated hyperfractionated thoracic radiotherapy with daily low-dose carboplatin in unresectable stage III non-small cell lung cancer: JCOG 9510.
Fujii T, Kunikane H, Okamoto H, Watanabe K, Kunitoh H, Mori K, Yokoyama A, Fukuda H, Tamura T, Saijo N. Fujii T, et al. Among authors: okamoto h. Jpn J Clin Oncol. 2009 Dec;39(12):784-90. doi: 10.1093/jjco/hyp102. Epub 2009 Sep 20. Jpn J Clin Oncol. 2009. PMID: 19770129 Clinical Trial.
Phase I/II trial of gemcitabine plus oral TS-1 in elderly patients with advanced non-small cell lung cancer: Thoracic oncology research group study 0502.
Seto T, Yamanaka T, Wasada I, Seki N, Okamoto H, Ogura T, Shibuya M, Takiguchi Y, Shinkai T, Masuda N, Ichinose Y, Eguchi K, Watanabe K. Seto T, et al. Among authors: okamoto h. Lung Cancer. 2010 Aug;69(2):213-7. doi: 10.1016/j.lungcan.2009.10.017. Epub 2010 Feb 13. Lung Cancer. 2010. PMID: 20153912 Clinical Trial.
Long-term administration of second-line chemotherapy with S-1 and gemcitabine for platinum-resistant non-small cell lung cancer: a phase II study.
Takiguchi Y, Seto T, Ichinose Y, Nogami N, Shinkai T, Okamoto H, Minato K, Seki N, Eguchi K, Kishi K, Nishikawa M, Watanabe K. Takiguchi Y, et al. Among authors: okamoto h. J Thorac Oncol. 2011 Jan;6(1):156-60. doi: 10.1097/JTO.0b013e3181f7c76a. J Thorac Oncol. 2011. PMID: 21107293 Free article. Clinical Trial.
Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.
Niho S, Kunitoh H, Nokihara H, Horai T, Ichinose Y, Hida T, Yamamoto N, Kawahara M, Shinkai T, Nakagawa K, Matsui K, Negoro S, Yokoyama A, Kudoh S, Kiura K, Mori K, Okamoto H, Sakai H, Takeda K, Yokota S, Saijo N, Fukuoka M; JO19907 Study Group. Niho S, et al. Among authors: okamoto h. Lung Cancer. 2012 Jun;76(3):362-7. doi: 10.1016/j.lungcan.2011.12.005. Epub 2012 Jan 14. Lung Cancer. 2012. PMID: 22244743 Free article. Clinical Trial.
Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301).
Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamoto N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H, Saijo N, Tamura T; Japan Clinical Oncology Group Lung Cancer Study Group. Atagi S, et al. Among authors: okamoto h. Lancet Oncol. 2012 Jul;13(7):671-8. doi: 10.1016/S1470-2045(12)70139-0. Epub 2012 May 22. Lancet Oncol. 2012. PMID: 22622008 Clinical Trial.
Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-naïve patients with advanced nonsquamous non-small-cell lung cancer.
Okamoto I, Aoe K, Kato T, Hosomi Y, Yokoyama A, Imamura F, Kiura K, Hirashima T, Nishio M, Nogami N, Okamoto H, Saka H, Yamamoto N, Yoshizuka N, Sekiguchi R, Kiyosawa K, Nakagawa K, Tamura T. Okamoto I, et al. Among authors: okamoto h. Invest New Drugs. 2013 Oct;31(5):1275-82. doi: 10.1007/s10637-013-9941-z. Epub 2013 Mar 10. Invest New Drugs. 2013. PMID: 23475281 Clinical Trial.
3,524 results